CAI Caris Life Sciences, Inc. | US1421521071
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 1.198.244.300 | 1.001.178.070 | 19.68% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 0,36 | 0,13 | 173.94% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 10 | 10 | 0.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |